| First Author | Zhang S | Year | 2015 |
| Journal | Cancer Res | Volume | 75 |
| Issue | 10 | Pages | 1936-43 |
| PubMed ID | 25808869 | Mgi Jnum | J:221116 |
| Mgi Id | MGI:5638264 | Doi | 10.1158/0008-5472.CAN-14-3303 |
| Citation | Zhang S, et al. (2015) Manic Fringe Promotes a Claudin-Low Breast Cancer Phenotype through Notch-Mediated PIK3CG Induction. Cancer Res 75(10):1936-43 |
| abstractText | Claudin-low breast cancer (CLBC) is a poor prognosis disease biologically characterized by stemness and mesenchymal features. These tumors disproportionately affect younger patients and women with African ancestry, causing significant morbidity and mortality, and no effective targeted therapy exists at present. CLBC is thought to originate from mammary stem cells, but little is known on how or why these tumors express a stable epithelial-to-mesenchymal transition phenotype, or what are the driving forces of this disease. Here, we report that Manic Fringe (Mfng), which encodes an O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase known to modify EGF repeats in the Notch extracellular domain, is highly expressed in CLBC and functions as an oncogene in this context. We show that Mfng modulates Notch activation in human and mouse CLBC cell lines, as well as in mouse mammary gland. Mfng silencing in CLBC cell lines reduced cell migration, tumorsphere formation, and in vivo tumorigenicity associated with a decrease in the stem-like cell population. Mfng deletion in the Lfng(flox/flox);MMTV-Cre mouse model, in which one-third of mammary tumors resemble human CLBC, caused a tumor subtype shift away from CLBC. We identified the phosphoinositide kinase Pik3cg as a direct transcriptional target of Mfng-facilitated RBPJkappa-dependent Notch signaling. Indeed, pharmacologic inhibition of PI3Kgamma in CLBC cell lines blocked migration and tumorsphere formation. Taken together, our results define Mfng as an oncogene acting through Notch-mediated induction of Pik3cg. Furthermore, they suggest that targeting PI3Kgamma may prove beneficial for the treatment of CLBC subtype. Cancer Res; 75(10); 1936-43. (c)2015 AACR. |
